Antivector Cellular Immunity

Reference work entry

Antivector cellular immunity in a vaccination may cause a serious problem if the vector, e.g., adenovirus, occurs in the population and if the animal/human cells have already developed antibodies against a particular serotype, thereby diminishing the effectiveness of such a vector. Antivector immunity can be circumvented by the use of a chimeric vector. In a novel vector the hypervariable region of the rare adenovirus serotype Ad48 replaced, in a rAd5 adenovirus-derived vector, the seven short hypervariable regions of the Ad5 hexon protein. The engineered vector expressed well the simian HIV Gag protein in naïve mice and rhesus monkeys and it did not show neutralizing suppression. Such a construct may open a new approach to vaccination and gene therapy (Roberts DM et al 2006 Nature [Lond] 441:239). human gene transfer, gene therapy, HIV, acquired immunodeficiency, hexon

Copyright information

© Springer Science+Business Media 2008